Franklin Resources Inc. decreased its position in Dexcom (NASDAQ:DXCM) by 1.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,165,883 shares of the medical device company’s stock after selling 14,636 shares during the period. Franklin Resources Inc. owned 1.34% of Dexcom worth $66,910,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of DXCM. The Manufacturers Life Insurance Company raised its stake in Dexcom by 12.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after acquiring an additional 354 shares in the last quarter. Amalgamated Bank increased its stake in Dexcom by 5.7% in the fourth quarter. Amalgamated Bank now owns 17,107 shares of the medical device company’s stock valued at $982,000 after purchasing an additional 924 shares during the period. Wedbush Securities Inc. increased its stake in Dexcom by 24.2% in the fourth quarter. Wedbush Securities Inc. now owns 5,589 shares of the medical device company’s stock valued at $321,000 after purchasing an additional 1,089 shares during the period. Dimensional Fund Advisors LP increased its stake in Dexcom by 0.9% in the third quarter. Dimensional Fund Advisors LP now owns 127,769 shares of the medical device company’s stock valued at $6,247,000 after purchasing an additional 1,095 shares during the period. Finally, Stifel Financial Corp boosted its holdings in shares of Dexcom by 15.2% in the third quarter. Stifel Financial Corp now owns 8,567 shares of the medical device company’s stock valued at $422,000 after acquiring an additional 1,129 shares in the last quarter.
DXCM traded down $2.13 during midday trading on Friday, hitting $70.15. 809,558 shares of the company’s stock traded hands, compared to its average volume of 1,324,492. Dexcom has a one year low of $42.62 and a one year high of $81.91. The firm has a market cap of $6,102.84, a PE ratio of -120.95 and a beta of -0.01. The company has a debt-to-equity ratio of 0.78, a quick ratio of 5.04 and a current ratio of 5.36.
Dexcom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, February 27th. The medical device company reported $0.10 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.07. The company had revenue of $221.00 million for the quarter, compared to analyst estimates of $217.82 million. Dexcom had a negative net margin of 6.99% and a negative return on equity of 13.99%. sell-side analysts anticipate that Dexcom will post -0.56 earnings per share for the current fiscal year.
In related news, EVP Richard Doubleday sold 1,638 shares of Dexcom stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $56.32, for a total value of $92,252.16. Following the completion of the transaction, the executive vice president now directly owns 65,049 shares of the company’s stock, valued at $3,663,559.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Terrance H. Gregg sold 10,000 shares of Dexcom stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total value of $568,600.00. Following the completion of the transaction, the insider now directly owns 484,559 shares of the company’s stock, valued at $27,552,024.74. The disclosure for this sale can be found here. Insiders have sold 35,854 shares of company stock worth $2,141,081 in the last quarter. Corporate insiders own 1.70% of the company’s stock.
Several analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Dexcom from a “hold” rating to a “sell” rating in a report on Friday, March 2nd. BMO Capital Markets upgraded shares of Dexcom to an “outperform” rating and set a $78.00 target price for the company in a research report on Thursday, March 29th. Piper Jaffray set a $80.00 price objective on shares of Dexcom and gave the company a “buy” rating in a research report on Thursday, March 29th. Goldman Sachs assumed coverage on shares of Dexcom in a research report on Wednesday. They set a “sell” rating and a $57.00 price target for the company. Finally, BidaskClub downgraded shares of Dexcom from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Dexcom currently has an average rating of “Buy” and a consensus target price of $66.91.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/franklin-resources-inc-sells-14636-shares-of-dexcom-inc-dxcm.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.